INS and obesity disorder: While C16:0 and C18:0 ceramides are considered central to the development of obesity, insulin resistance, and metabolic diseases59,78, there is insufficient evidence to support negative regulatory effects of very-long-chain ceramides on insulin sensitivity and metabolic outcomes2.